SIZE XSSIZE SMSIZE MDSIZE LG

BCOP Self-Study Online Module Release I

The Self-Study Online Modules will cover all BCOP domains and multiple hematology/oncology patient populations, you will learn from:

  • Leading experts from a variety of specialties and settings
  • Therapeutic developments translated into case-based reviews
  • Application of information to practice based scenarios

The Self-Study Online Module features current articles from primary oncology literature which are available on demand and allow you to complete at your convenience.  The modules will allow the learner to apply literature they have and read in patient cases and/or case – based discussion.  Credit given per module – choose one or all.

Module 1: Hodgkin Lymphoma: Where Do All the Pieces Fit? (1.5 BCOP/ACPE)

Module 2: Updates in the Treatment of Acute Myeloid Leukemia (2.5 BCOP/ACPE)

Module 3: Biomarkers in Immunotherapy (1.5 BCOP/ACPE)

Module 4: Treatment of NSCLC with a Focus on Newer Therapies (2.5 BCOP/ACPE)

Each module will include access to articles, pre-assessment questions, patient cases and/or case—based discussion and the BCOP web-based post-test. Your purchase includes all four modules.  You may choose to complete all 4 modules or select ones individually and still receive BCOP credit for modules which achieve passing scores.

New this year, the case studies will count towards the overall test score for the BCOP credit.  Therefore, between your results in the Case Studies and the Posttest questions will determine your total score which still must meet the 75% threshold for passing to earn BCOP credit.  

Release I offers up to 8 BCOP/ACPE credits 

HOPA Member Price: $165
Non-Member Price: $225

Purchase Now

Can be purchased as part of the 2018 BCOP Program Bundle.

Credit Designation

Accreditation Statement:

logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. BCOP test must be completed by October 27, 2018.

education speaker bpslogoThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. Test must be completed by October 27, 2018.

Activity type:

Application.

Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.


Module 1: Hodgkin Lymphoma: Where Do All the Pieces Fit?

Laura Tang, PharmD BCOP
Memorial Sloan Kettering Cancer Center

The management of Hodgkin Lymphoma continues to advance with the FDA approval of nivolumab and data emerging with brentuximab vedotin, expanding its place in therapy. This session will review recent literature updates to help in determining where all of these pieces fit in a patient’s treatment plan- nivolumab, brentuximab vedotin, and traditional chemotherapeutic agents.

Speaker

laura tang

Laura Tang, PharmD BCOP

Laura Tang, PharmD, BCOP is a Clinical Pharmacy Specialist in lymphoma at Memorial Sloan Kettering Cancer Center in New York, NY. Dr. Tang received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy in Philadelphia, PA in 2011. Before completing her residency training, Dr. Tang was a staff pharmacist at Pinnacle Health System in Harrisburg, PA. She completed her PGY1 Pharmacy Practice Residency at Penn State Milton S. Hershey Medical Center and PGY2 Oncology Pharmacy Residency at the University of Michigan Health System. 

Disclosure: NCCN – Speaker - honoraria

Learning Objectives:

  • Explore the role of brentuximab vedotin in the treatment of Hodgkin lymphoma.
  • Describe the unique mechanism of action, efficacy, and safety of nivolumab for the treatment of Hodgkin lymphoma.
  • Review the efficacy and safety of the bendamustine containing regimen BeGeV.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hour (.15 CEUs) under the ACPE universal activity number 0465-0000-18-055-H04-P.

Module 2: Updates in the Treatment of Acute Myeloid Leukemia

Sherry Williams, PharmD BCOP
Ohio State University James Cancer Center

Three targeted treatment options have recently been FDA approved for the treatment of acute myeloid leukemia (AML).  This self-study will review the literature supporting the use of the targeted agents midostaurin, enasidenib, and gemtuzumab ozogamicin in the treatment of AML.  Participants will review 3 clinical trials that validate the use of these agents as targeted therapy options.  Study results will then be applied to patient scenarios in order to select optimal therapy.

Speaker

sherry williams

Sherry Williams PharmD BCOP

Sherry Williams, PharmD BCOP, is a Clinical Pharmacist Specialist at the Ohio State University James Cancer Center and Solove Research Institute. Dr. Williams received her pharmacy degree from Chicago State University – College of Pharmacy. She completed her PGY1 Pharmacy Practice Residency at Rush University Medical Center in Chicago, Illinois and PGY2 Oncology Pharmacy Residency at H. Lee Moffitt Cancer Center in Tampa, Florida. Her practice area is inpatient Acute Leukemia and Autologous Stem Cell Transplantation. Dr. Williams also serves as a preceptor for both PGY1 and PGY2 residency programs at the Ohio State University.

Disclosure: No financial relationships exist with commercial interests.

Learning Objectives:

  • Identify the molecular target and mechanism of action of midostaurin, enasidenib, and gemtuzumab ozogamicin.
  • Evaluate the data supporting the use of midostaurin, enasidenib, and gemtuzumab ozogamicin in the treatment of AML.
  • Select optimal therapy for a patient with AML based on patient and disease specific information.
  • Identify appropriate supportive care and monitoring strategies for patients receiving treatment with midostaurin, enasidenib and gemtuzumab ozogamicin.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.5 contact hour (.25 CEUs) under the ACPE universal activity number 0465-0000-18-041-H04-P.


Module 3: Biomarkers in Immunotherapy

Patrick Kiel, PharmD BCPS BCOP
IU Simon Cancer Center
Precision Genomics Program

As immunotherapy continues to be added to the armamentarium of anti-cancer therapy the evaluation of biomarkers to assess efficacy and resistance continue to emerge.  Coupled with the advent of the precision medicine age and next-generation sequencing becoming a standard of care in oncology, clinical pharmacists will need to be able to assess the evolving methods of biomarkers.   This module will highlight recently published articles that address the expanding landscape of immunotherapy.

Speaker

patrick kiel

Patrick J. Kiel, PharmD BCPS BCOP

Patrick J. Kiel, PharmD BCPS BCOP is a clinical pharmacy specialist at Indiana University (IU) Simon Cancer Center in Indianapolis, Indiana.  He received his Doctor of Pharmacy degree from Midwestern University Chicago College of Pharmacy.  Dr. Kiel completed his PGY1 residency at Rush University Medical Center in Chicago, Illinois, and his PGY2 specialty residency in hematology/oncology at Indiana University Hospital.  He provides clinical services for the Precision Genomic Program at the IU Simon Cancer Center.  His research interests include genomically guided therapy in patients with refractory metastatic cancer.

Disclosures: Celgene – Speaker – Honoraria, Takeda – Speaker – Honoraria, Genentech – Speaker - Honoraria

Learning Objectives:

  • Describe key findings of the role of tumor mutation burden and as a predictor of response to immunotherapy
  • Explain the role of mismatch-repair deficiency in immune evasion and the clinical benefit that immunotherapy provide.
  • Assess potential resistance markers to immunotherapy.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.5 contact hour (.25 CEUs) under the ACPE universal activity number 0465-0000-18-056-H04-P.


Module 4: Treatment of NSCLC with a Focus on Newer Therapies 

Janine Walsh, PharmD BCOP
Dana Farber Cancer Institute

NSCLC treatment has evolved over the past year with comprehensive molecular testing and various treatment strategies involving immunotherapy in the adjuvant setting as well as in patients with advanced disease. This module will highlight these changes along with new treatment paradigms in patients with ALK positive NSCLC based on recent data. Participants will review two clinical trials and one review article focusing on molecular targets for NSCLC. Utilizing the information reviewed in these articles, participants will then apply this content to patient scenarios in order to select optimal therapy. 

Speaker

janine walsh

Janine Walsh, PharmD BCOP

Janine Walsh, PharmD BCOP, graduated from Northeastern University in Boston in 2008, where she earned her PharmD degree.  Dr. Walsh completed her PGY1 pharmacy residency training at Dartmouth-Hitchcock Medical Center in Lebanon, NH in 2009, and went on to complete her PGY2 pharmacy residency in hematology/oncology at Boston Medical Center in 2010.  Dr. Walsh has experience in a variety of practice settings, including smaller community hospitals as well as large academic medical centers.  She is currently the thoracic medical oncology pharmacy specialist at Dana Farber Cancer Institute in Boston.

Disclosures: No financial relationships exist with commercial interests.

Learning Objectives:

  • Identify the most appropriate initial therapy based on molecular diagnostic study results for a patient with advanced non-small cell lung cancer (NSCLC).
  • Review recent updates in the treatment of patients with anaplastic lymphoma kinase (ALK) mutation positive NSCLC.
  • Discuss trial data focusing on the efficacy and toxicity of durvalumab in patients with NSCLC who have completed chemoradiation.
  • Evaluate an immunohistochemical assessment of PD-L1 expression and its implication in the treatment of NSCLC.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hour (.15 CEUs) under the ACPE universal activity number 0465-0000-18-057-H04-P.

 

 

 

xs
sm
md
lg